Table 1.
Patient, disease and transplant characteristics
| Characteristics | MRD (n=47) | UCB (n=43) | P-value |
|---|---|---|---|
| Median age, years (range) | 58 (55-70) | 59 (55-69) | 0.22 |
| Gender, male | 33 (70%) | 32 (74%) | 0.66 |
| Median weight, kilograms (range) | 78 (55-120) | 79 (50-130) | 0.96 |
| Race | 0.88 | ||
| White | 43 (91%) | 38 (88%) | |
| Other | 4 (9%) | 5 (12%) | |
| Diagnosis | 0.07 | ||
| Acute myeloid leukemia | 10 (21%) | 19 (44%) | |
| Acute lymphoblastic leukemia | 2 (4%) | 2 (5%) | |
| Chronic myeloid leukemia | 2 (4%) | 1 (2%) | |
| Chronic lymphocytic leukemia | 3 (7%) | 2 (5%) | |
| Myelodysplastic syndrome | 6 (13%) | 10 (23%) | |
| Non-Hodgkin’s lymphoma | 14 (30%) | 7 (16%) | |
| Hodgkin’s lymphoma | 2 (4%) | 0 | |
| Multiple myeloma | 6 (13%) | 0 | |
| Other 1 | 2 (4%) | 2 (5%) | |
| Disease risk 2 | 0.33 | ||
| Standard | 9 (19%) | 12 (28%) | |
| High | 38 (81%) | 31 (72%) | |
| Prior HCT 3 | 9 (19%) | 3 (7%) | 0.09 |
| Median time from diagnosis to HCT, months (range) | 25 (3-154) | 13 (3-250) | 0.24 |
| HCT-specific comorbidity index score 4 | 0.10 | ||
| 0 | 7 (16%) | 15 (36%) | |
| 1-2 | 19 (43%) | 13 (31%) | |
| ≥ 3 | 18 (41%) | 14 (33%) | |
| Conditioning regimen | 0.13 | ||
| Cy/Flu/TBI | 33 (70%) | 36 (84%) | |
| Other 5 | 14 (30%) | 7 (16%) | |
| ATG used in conditioning | 6 (13%) | 17 (40%) | <0.01 |
| HLA compatibility6 | <0.01 | ||
| 6/6 antigen match | 47 (100%) | 3 (7%) | |
| 5/6 antigen match | 0 | 13 (30%) | |
| 4/6 antigen match | 0 | 27 (63%) | |
| Recipient-donor CMV serologic status | 0.02 | ||
| Recipient negative-donor negative | 16 (34%) | 18 (42%) | |
| Recipient negative-donor positive | 8 (17%) | 0 | |
| Recipient positive | 23 (49%) | 25 (58%) | |
| Median cell dose, x108NC/kg (range) | 9.2 (3.0-21.2) | 0.4 (0.2-0.8) | <0.01 |
| Median CD34+ cell dose, x106cells/kg (range) | 5.3 (1.2-15.5) | 0.4 (0.1-1.7) | <0.01 |
| Median follow up, months (range) | 37 (18-61) | 24 (12-44) | 0.33 |
MRD — matched related donor; UCB — unrelated umbilical cord blood donor; MDS — myelodysplastic syndrome; HCT — hematopoietic cell transplantation; ATG — anti-thymocyte globulin; Cy/Flu/TBI — cyclophosphamide/fludarabine/total body irradiation; HLA — human leukocyte antigen; CMV — cytomegalovirus; NC — nucleated cells
Includes one patient each with renal cell carcinoma and myelofibrosis in MRD group and renal cell carcinoma and aplastic anemia in UCB group.
Standard risk disease - acute leukemia in first complete remission, chronic myeloid leukemia in first chronic phase, myelodysplastic syndrome refractory anemia, non-malignant hematological disorder; High risk disease — all other disease categories.
All had prior autologous HCT except for 1 patient in MRD group who had received a MRD myeloablative allogeneic HCT for MDS 8 years prior.
Excludes 4 patients (MRD=3, UCB=1) for whom sufficient data was not available to calculate the HCT-specific comorbidity score.
Includes busulfan/fludarabine/TBI (n=16) and busulfan/cladribine/TBI (n=5)
Worst HLA match for patients undergoing UCB transplantation using two UCB units